ASX:ATXPharmaceuticals, Biotechnology & Life SciencesBiotechnology

AMPLIA THERAPEUTICS ORD

$0.135

Day Range

$0.135 - $0.140

52 Week Range

$0.049 - $0.425

Volume

86.82K

Avg Volume (10D)

1.43M

Market Cap

$69.26M

Price Chart

Market Statistics

Open$0.140

Previous Close$0.135

Day High$0.140

Day Low$0.135

52 Week High$0.425

52 Week Low$0.049

Valuation

Market Cap69.26M

Shares Outstanding513.07M

Price to Book1.61

Trading Activity

Volume86.82K

Value Traded12.15K

Bid$0.135 × 306,630

Ask$0.140 × 353,852

Performance

1 Day-3.57%

5 Day-12.90%

13 Week3.85%

52 Week141.07%

YTD-10.00%

Technical Indicators

RSI (14)39.66

50-Day SMA$0.157

200-Day SMA$0.155

Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG

Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.

1 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs

Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.

1 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial

Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.

2 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial

Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]

2 min read

Imelda Cotton